The first CRISPR medicine was approved yesterday. 😲 ... And, it's in the UK!! The decision could transform the treatment of sickle-cell disease. This is the first medicine based on CRISPR technology that has been approved... ANYWHERE!! (Perhaps the only benefit of Brexit 🤣) Link in the comments!
Moxee
Staffing and Recruiting
Leeds, England 1,190 followers
🧬 Talent Acquisition should be as precise as DNA Sequencing.
About us
We help your 'Omics company to hire the brains behind your innovations. Your sourcing strategy should be as precise as your sequencing. We've witnessed the frustrations firsthand. Subpar candidates, missed opportunities, and hiring processes built with other domains in mind. ———————————————————————————————— Depending on the defined goals, Moxee will suggest: • RPO Services- for 4+ roles and project preventing hires. • Consultancy - for start-ups with embedded HR/TA who need some words of wisdom. Let us handle recruitment on their behalf, or empower them with the knowledge to do it themselves. • Search and Selection - for those extra tricky, specific hires. No hire - no fee! • Executive Search - because finding the perfect mutation for your C-Suite team is too important to leave to gut feelings, especially when our leadership teams typically lack diversity. (7.9% of executive teams in STEM are female, for example) We’re not just another Talent Agency lost in a sea of sequencing jargon. ———————-———————-———————-————————— 𝗥𝗘𝗖𝗥𝗨𝗜𝗧𝗜𝗡𝗚 𝗙𝗢𝗥: • Genomics • Proteomics • Transcriptomics • Metabolomics • Epigenomics • Pharmacogenomics • Lipidomics • Agrigenomics • NGS • Spatial Biology • Single-cell Analysis • CRISPR/Cas9 Genome Editing • Data Integration and Analysis • Bioinformatics • Biomarker Discovery • Precision Medicine • Computational Chemistry • Computational Biology ———————-———————-———————-————————— 📧 hello@moxee-search.com ———————-———————-———————-—————————
- Website
-
https://moxee-search.com/
External link for Moxee
- Industry
- Staffing and Recruiting
- Company size
- 2-10 employees
- Headquarters
- Leeds, England
- Type
- Privately Held
- Founded
- 2023
- Specialties
- life sciences, recruitment, biotechnology, genomics, proteomics, Molecular Biology, Bioinformatics, Single-Cell, Transcriptomics, Metabolomics, Epigenomics, Personalized Medicine, Precision Medicine, CRISPR, Gene Editing, Next Generation Sequencing, Computational Biology, Computational Chemistry, Spatial Biology, RNA-Seq, and Agrigenomics
Locations
-
Primary
Get directions
Redvers Close
Leeds, England LS16 6, GB
Employees at Moxee
Updates
-
Last week was HUGE for funding! 💸 👏 Here's the biotech round-up: [1] Genezen - Cell Therapy, Indiana - $18,500,000 (Venture Round) [2] Stellaromics Inc. - Multi-Omics, Massachusetts - $25,000,000 (Series A) [3] Progenx - Neuroscience, New York - $15,000,000 (Series A) [4] GENOME INSIGHT INC. - Multi-Omics, New York - $23,000,000 (Series A) [5] Gate Bioscience - Protein Degradation, California - $60,000,000 (Series A) [6] Siren Biotechnology - AAV immuno-gene therapy, California - $4,000,000 (Grant) [7] Lucid Diagnostics - Cancer Dx, New York - $5,000,000 (Venture Round) [8] Aqtual, Inc. - Precision Medicine, California - $16,000,000 (Series A) [9] Engine Biosciences - Biomarker Discovery, California - $27,000,000 (Series A) [10] Annovis Bio, Inc. - Alzheimer’s and Parkinson’s, Pennsylvania - $7,500,000 (Post) [11] Annovis Bio, Inc. - Alzheimer’s and Parkinson’s, Pennsylvania - $7,500,000 (Post) [12] 100X Bioassay - T-Cell Research, Massachusetts - $40,000 (Pre-seed) [13] BRAINBox Solutions, Inc. - mTBI, Diagnosis & Prognosis, Virginia - (Series B) [14] Granata Bio - Fertility Solutions , Massachusetts - $96,667 (Seed Round) [15] MapLight Therapeutics, Inc. - Therapeutics for CNS disorders, California - $225,000,000, (Series C) #biotech #funding
-
London-based Automata, a biotech focusing on robotic automation for life sciences labs, has raised $40 million in funding. 👏 🤑 👏 🤑 This follows a $50 million Series B round in January 2022. Investors include Dimension and A.P. Moller Holding, along with existing investors. Automata has experienced significant growth with a 150% revenue increase and a 12-fold rise in live system hours. Their LINQ automation platform offers adaptability for labs in various sectors, helping streamline processes and enhance efficiency in the face of changing scientific demands.
-
-
Adela, Inc. - a pioneer in blood testing for MRD monitoring and early cancer detection has secured $48 million in financing. 👏 This funding round involves existing investors like F-Prime Capital, OrbiMed, Deerfield Management, Decheng Capital, and RA Capital Management, as well as new investor... Labcorp! These funds will support the advancement of Adela's tech platform, including their MRD monitoring product. They also plan to develop a multi-cancer early detection product based on the same platform. Lisa Alderson, an accomplished healthcare leader, has been appointed as Adela's interim CEO. #biotech #funding #MoxeeMolecular
-
-
Fed up with the lack of Bioinformatics opportunities in Massachusetts? Lacking the opportunity to utilise your commercial acumen? Unable to manage independent projects? Frustrated with PhD's as a non-negotiable? Bioinformatician of any seniority, with experience in Mass Spec or Proteomic data sets? Send an email to hello@moxee-search.com for a link to our Calendar. 👇
-
-
Moxee is feelin' extra moxie today. Not only is it nearly the weekend... But we've been nominated in Labiotech.eu's "10 biotech recruitment companies to watch." 🔬 If you're: - operating in Multi-Omics, Gene Editing or Diagnostics - have less than 260 employees - open to change - struggling with the influx in LI applications, but still can't find "the one" Book a 30-minute discovery call here ---> https://lnkd.in/eft68WaS
-
🧬 Multi-Omics + Bioinformatics, Data & Computational Recruitment | 👩🔬 Founder @ Moxee | 🦋 T1 Diabetic |
My most asked question by Biotech candidates right now is: "How is the job market, Amber?" Well... It's complicated. 🤣 1) There are a lot of challenges, but even more promise. It's a tough environment for VC funding and IPOs, understandably. 2) Inflation isn’t driving the tightening. It’s the monetary policy of raising interest rates responding to inflation that is causing the tightening. 3) Salaries (generally) have dropped slightly. We are fighting more so now for fair (15%+) pay rises than six months ago... even if the candidate is from a direct competitor and brings a wealth of relevant experience. 4) There are widespread lay offs, company closures, and hiring freezes. (Last week = BMS, EQRx, ADC, Novavax, Gossamer Bio and Athenex) 5) Job Offers have become slightly more lenient in regards to education requirements. 6) Lots of people applying to fewer jobs: (i) Lots of people applying due to lay offs and closures and (ii) fewer jobs due to hiring freezes, inflation, and decreased funding sources. I've had a HUGE influx of inbound candidates. 7) Manufacturing and CRO's have been the least affected. There is tons of hiring and positive cash flow happening. 8) Theres been a huge influx in Computational / Bioinformatics / Data Science openings... duh. These are also the roles which hiring managers need the most support with. 9) My network reports that recruitment agency outreach has dropped off the face of the Earth. HOWEVER... We are still seeing net market growth. Most of my network who are affected by layoffs are employed a few weeks later. Biotech Jobs posted yesterday in the USA = 3,201 Biotech Jobs posted yesterday in the UK = 362 There is always going to be demand for great people in the industry. Saving lives will always be necessary, despite economic downturns. The way for you to stand out among other candidates is going to be a strategic job hunt. Applying to 100 roles on Linkedin and hoping for a response no longer cuts it. PS - Fierce Biotech's layoff tracker is fabulous. BioPharmGuy is invaluable for entry-level Biotech careers. Link in the comments! #lifesciences
-
Cell and Gene therapies are changing people's lives. 😄 They fix the root cause of an illness at a super tiny level. Usually, this is a rare disease that people inherit and can be really dangerous. Sometimes, there aren't many treatments available for these diseases. Professor Rafael J. Yáñez-Muñoz, from Royal Holloway University of London, says that these therapies were first developed for rare diseases caused by a single messed-up gene. But now, they're being used to treat more common diseases too. This is exciting because it means the technology can help lots of people. One example is a treatment called CAR T-cell therapy. It helps people with certain blood cancers. Scientists change a patient's T cells in a lab and then put them back in the body to fight the disease. So far, the US Food and Drug Administration (FDA) has approved 24 cell and gene therapies. These treatments have changed the lives of patients with rare diseases like inherited blindness and neuromuscular conditions. To make gene therapy work, scientists need to deliver the new genes to the right cells in the body. They use special vehicles called vectors to do this. Many gene therapies use modified viruses as vectors because they're good at entering cells. But scientists are also using other methods, like tiny fat particles, to deliver the genes. But, there's another challenge with gene therapy. Scientists need to make sure the gene is expressed at the right level in the affected cells. If it's too much or too little, it can cause problems. Recently, scientists made a system called Xon that acts like a dimmer switch. It can control how much gene is expressed using a special drug. This is a big step forward for gene therapy. 👏 #biotechjobs #lifesciences